Literature DB >> 25636468

Induction of colorectal cancer in mice and histomorphometric evaluation of tumors.

Ilija Crncec1, Paulina Pathria, Jasmin Svinka, Robert Eferl.   

Abstract

Colorectal cancer (CRC) originates from the epithelial cells lining the colon or rectum of the gastrointestinal tract and represents the third most common form of cancer worldwide. CRC is frequently associated with Colitis Ulcerosa or Crohn's Disease demonstrating the tumor-promoting role of inflammation. Colorectal tumor cells establish heterotypic interactions with inflammatory cells and cancer-associated fibroblasts in the tumor stroma that support tumor angiogenesis and are essential for tumor progression. Therefore, establishment of suitable mouse models mimicking the inflammatory etiology of CRC is important. Here we describe methods to induce CRC in mice, to quantify tumor parameters (multiplicity, tumor load, mean tumor size), and to analyze the cellular composition of the CRC tumor stroma.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25636468     DOI: 10.1007/978-1-4939-2297-0_7

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  8 in total

1.  AOM/DSS Induced Colitis-Associated Colorectal Cancer in 14-Month-Old Female Balb/C and C57/Bl6 Mice-A Pilot Study.

Authors:  Martin Schepelmann; Nadja Kupper; Valeriya Gushchina; Ildiko Mesteri; Teresa Manhardt; Stefan Moritsch; Christian Müller; Karina Piatek; Martina Salzmann; Andrea Vlasaty; Robert Eferl; Enikö Kallay
Journal:  Int J Mol Sci       Date:  2022-05-09       Impact factor: 5.923

Review 2.  Inflammatory bowel disease, colorectal cancer and type 2 diabetes mellitus: The links.

Authors:  Abdo Jurjus; Assad Eid; Sahar Al Kattar; Marie Noel Zeenny; Alice Gerges-Geagea; Hanine Haydar; Anis Hilal; Doreid Oueidat; Michel Matar; Jihane Tawilah; Inaya Hajj Hussein; Pierre Schembri-Wismayer; Francesco Cappello; Giovanni Tomasello; Angelo Leone; Rosalyn A Jurjus
Journal:  BBA Clin       Date:  2015-11-05

3.  Assessment of murine colorectal cancer by micro-ultrasound using three dimensional reconstruction and non-linear contrast imaging.

Authors:  Jessica L Freeling; Khosrow Rezvani
Journal:  Mol Ther Methods Clin Dev       Date:  2016-11-30       Impact factor: 6.698

4.  MicroRNA-146a limits tumorigenic inflammation in colorectal cancer.

Authors:  Amrendra K Ajay; Mai Fujiwara; Lucien P Garo; Galina Gabriely; Radhika Raheja; Chantal Kuhn; Brendan Kenyon; Nathaniel Skillin; Ryoko Kadowaki-Saga; Shrishti Saxena; Gopal Murugaiyan
Journal:  Nat Commun       Date:  2021-04-23       Impact factor: 14.919

5.  Tyk2 is a tumor suppressor in colorectal cancer.

Authors:  Stefan Moritsch; Bernadette Mödl; Irene Scharf; Lukas Janker; Daniela Zwolanek; Gerald Timelthaler; Emilio Casanova; Maria Sibilia; Thomas Mohr; Lukas Kenner; Dietmar Herndler-Brandstetter; Christopher Gerner; Mathias Müller; Birgit Strobl; Robert Eferl
Journal:  Oncoimmunology       Date:  2022-09-26       Impact factor: 7.723

6.  CDK15 promotes colorectal cancer progression via phosphorylating PAK4 and regulating β-catenin/ MEK-ERK signaling pathway.

Authors:  Chuntian Huang; Ruijuan Du; Xuechao Jia; Kangdong Liu; Yan Qiao; Qiong Wu; Ning Yao; Lu Yang; Liting Zhou; Xuejiao Liu; Pu Xiang; Mingxia Xin; Yan Wang; Xiaojie Chen; Dong Joon Kim; Zigang Dong; Xiang Li
Journal:  Cell Death Differ       Date:  2021-07-14       Impact factor: 15.828

7.  STAT1 is a sex-specific tumor suppressor in colitis-associated colorectal cancer.

Authors:  Ilija Crnčec; Madhura Modak; Claire Gordziel; Jasmin Svinka; Irene Scharf; Stefan Moritsch; Paulina Pathria; Michaela Schlederer; Lukas Kenner; Gerald Timelthaler; Mathias Müller; Birgit Strobl; Emilio Casanova; Editha Bayer; Thomas Mohr; Johannes Stöckl; Karlheinz Friedrich; Robert Eferl
Journal:  Mol Oncol       Date:  2018-02-20       Impact factor: 6.603

8.  Myeloid PTEN deficiency impairs tumor-immune surveillance via immune-checkpoint inhibition.

Authors:  M Kuttke; E Sahin; J Pisoni; S Percig; A Vogel; D Kraemmer; L Hanzl; J S Brunner; H Paar; K Soukup; A Halfmann; A M Dohnal; C W Steiner; S Blüml; J Basilio; B Hochreiter; M Salzmann; B Hoesel; G Lametschwandtner; R Eferl; J A Schmid; G Schabbauer
Journal:  Oncoimmunology       Date:  2016-03-28       Impact factor: 7.723

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.